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BCVA            Best Corrected Visual Acuity 
ICG               Indocyanine green 
IOP               Intraocular pressure 
MIST             Micro-invasive suture trabeculotomy 
Nd: YAG       Neodymium-doped yttrium aluminium garnet 
NPGS           Non-penetrating glaucoma surgery 
OAG             Open angle glaucoma 
SC                Schlemm’s canal 
TDM           Trabeculo-Descemet membrane 
TM                Trabecular meshwork  
TSCPC         Transscleral cyclophotocoagulation 
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1. Introduction and aim of work 
1.1. Glaucoma 
1.1.1. Definition 
The term “glaucoma” refers to a large number of diseases. The common feature 
of all glaucomas is a distinctive progressive optic neuropathy, which derives 
from various risk factors. Glaucomatous optic neuropathy is associated with a 
gradual loss of the visual field, which can lead to total, irreversible blindness if 
the disorder is not diagnosed and treated properly (Azuara-Blanco et al., 2001). 
Glaucomatous optic neuropathy is not the disease; it is the end-result of several 
as yet unidentified cellular disease processes (Schacknow and Samples, 2010). 
 
Historically, glaucomatous eyes were hardly to recognize till the invention of 
ophthalmoscopy by Helmholz in the nineteenth century, and its use by Albrecht 
von Graefes to describe the atrophy and cupping of the optic nerve head 
(Shaffer, 1996). As our understanding of the disease pathomechanisms 
increases and technology advances, treatment strategies become more 
sophisticated. 
 
 
1.1.2. Epidemiology 
Glaucoma is the second leading cause of blindness worldwide after cataract, 
with approximately 8.4 million people bilaterally blind from glaucoma (Quigley 
and Broman, 2006). Glaucoma is estimated to affect about 60.5 million people 
worldwide representing 2.65% of the adult population older than 40 years in 
2010 (Quigley and Broman, 2006, Resnikoff et al., 2004). In Germany, 
glaucoma is estimated to be the third leading cause of blindness in 2000 with an 
incidence of 1.6/100,000 (Krumpaszky et al., 1999). Twenty percent of all cases 
of legal blindness in people aged 75 years and older were due to glaucoma 
(Krumpaszky et al., 1999). 
 
 
1.1.3. Anatomy of the anterior chamber angle 
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 Figure (1)  Microanatomy of iris root, trabecular meshwork: Fuchs’ roll (FR), uveocorneal (UC) and 
scleral corneal portion (SC) of trabecular meshwork, collector channels (CC), scleral spur (SS), ciliary 
muscle (CM), Schwalb’s line (SL), Schlemm’s canal (pink); ciliary arterial circle of ciliary body (red) may be 
located in front of the ciliary muscle, but usually is embedded in the ciliary muscle. Note that the thinnest 
portion of the iris is located peripheral to Fuchs’ roll.(Naumann et al., 2011) 
 
 
The anterior chamber angle as viewed by gonioscopy (Alward and Allen, 1994, 
Kanski, 2007): 
 
- Root of the iris 
The iris generally inserts at a variable level into the face of the ciliary body. 
 
-Anterior border of ciliary body  
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There are two major muscle groups in the ciliary body: the circular muscle 
fibers, which are responsible for accommodation, and the longitudinal muscle 
fibers, which control the outflow of aqueous by pulling open the trabecular 
meshwork and Schlemm’s canal. 
 
-  Scleral spur 
The longitudinal muscle of the ciliary body attaches to the scleral spur and 
opens the trabecular meshwork by pulling on the Trabecular Meshwork. 
 
-Trabecular meshwork 
It is a sieve-like structure at the angle of the anterior chamber extending 
between the scleral spur and Schwalbe’s line and it is composed of the 
following three portions: 
 
   
a    Uveal meshwork is the innermost portion and consists of cord-like 
endothelial cell-covered strands arising from the iris and ciliary body 
stroma, and extending from the root of the iris to Schwalbe's line. The 
intertrabecular spaces are relatively large and offer little resistance to the 
passage of aqueous. 
   
b    Corneoscleral meshwork forms the larger middle portion which extends 
from the scleral spur to Schwalbe's line. The layers are sheet-like and 
composed of connective tissue strands also with overlying endothelial-
type cells. The intertrabecular spaces are smaller than those of the uveal 
meshwork, conferring greater resistance to flow. 
   
c    Juxtacanalicular (cribriform) meshwork is the outer part of the trabeculum, 
and links the corneoscleral meshwork with the endothelium of the inner 
wall of the Schlemm’s canal. This offers the major proportion of normal 
resistance to aqueous outflow, consisting of cells embedded in a dense 
extracellular matrix with narrow intercellular spaces. 
 
-Schlemm’s canal 
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A circumferential 190-350 µm diameter tube at the base of the scleral sulcus, 
Schlemm's canal collects aqueous and drains it into the venous system. 
Schlemm's canal is bridged by septa, which provide some support. 
 
 -Schwalbe's line 
Schwalbe’s line occurs in a 50-150 µm transition zone (zone S) between the 
trabecular meshwork and the corneal endothelium. It is the anterior border of 
the trabecular meshwork and the posterior border of Descemet's membrane. 
 
 
 
 
1.1.4. Flow of aqueous humor 
Aqueous humor is produced by the ciliary body and is secreted into the 
posterior chamber. Most of this fluid then flows into the anterior chamber and 
drains out of the chamber angle via one of two outflow pathways (Alward and 
Allen, 1994, Choplin and Lundy, 2007a, Kanski, 2007): 
 
Trabecular (conventional) route: 
Approximately 90% of aqueous outflow is through the trabecular meshwork. 
This flow is pressure-dependent, increasing as intraocular pressure increases. 
Aqueous humor flowing through the trabecular meshwork enters Schlemm's 
canal and from there flows into the scleral, episcleral, and conjunctival venous 
systems. For aqueous to exit the eye by this route, the intraocular pressure 
must be higher than the episcleral venous pressure. At pressures below 
episcleral venous pressure (8-15 mm Hg) all aqueous outflow must be via non-
conventional routes. 
 
Uveoscleral (unconventional) route: 
Accounts for the remaining 10% in which aqueous passes across the face of 
the ciliary body into the suprachoroidal space and is drained by the venous 
circulation in the ciliary body, choroid and sclera. 
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1.1.5. Classification of glaucoma 
Based on the newest guidelines of the European Glaucoma Society, glaucoma 
is classified as follows (Society, 2014): 
1. Primary congenital forms 
-Primary congenital glaucoma / childhood glaucoma 
-Glaucoma associated with congenital anomalies 
2. Primary open-angle glaucoma 
-Primary juvenile glaucoma. 
-Primary open angle glaucoma / high-pressure glaucoma 
-Primary open angle glaucoma / normal-pressure glaucoma 
-Primary open angle glaucoma – suspect 
3. Secondary open angle glaucoma 
-Secondary open angle glaucoma caused by ocular disease 
-Exfoliative glaucoma 
-Pigmentary glaucoma 
-Lens induced secondary open angle glaucoma. 
-Glaucoma associated with intraocular hemorrhage 
-Uveitic glaucoma 
-Glaucoma due to intraocular tumors 
-Glaucoma associated with retinal detachment. 
-Open angle glaucoma due to ocular trauma 
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-Iatrogenic secondary open angle glaucoma 
-Glaucoma due to corticosteroid treatment 
-Secondary open angle glaucoma due to ocular surgery and laser 
-Glaucoma caused by increased episcleral venous pressure 
4. Primary angle closure 
-Acute angle closure 
-Intermittent angle closure 
-Chronic angle closure 
-Status post acute angle closure attack 
5. Secondary angle closure 
-Secondary angle closure with papillary block 
-Secondary angle closure with anterior “pulling” mechanism without papillary 
block: 
e.g. neovascular glaucoma, peripheral anterior synechia, etc. 
-Secondary angle-closure with posterior “pushing” mechanism without papillary 
block: 
e.g. Aqueous misdirection glaucoma, iris and ciliary body cyst, silicon oil or gas 
tamponade implanted in the vitreous cavity, uveal effusion syndrome, 
retinopathy of prematurity (Stage V).  
 
1.1.6. Spectrum of glaucoma 
Glaucoma is a wide spectrum of clinical entities that include many ocular and 
systemic conditions. At one end of this spectrum is the quiet, painless eye of a 
patient with primary open-angle glaucoma who may be unaware of his disease. 
Because of its quite slow progression of optic nerve damage, glaucoma is 
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commonly called the “silent thief of vision” and patients may not present until 
late stage of disease.  At the other extreme is the patient with acute angle 
closure glaucoma who presents with eye pain, decreased vision, and possibly 
even systemic symptoms such as nausea and vomiting (Choplin and Lundy, 
2007b). 
 
Being the commonest form of glaucoma in Europe and worldwide (Quigley and 
Broman, 2006) , primary open angle glaucoma was a main focus of research in 
the last decades. 
 
1.1.7. Pathophysiology of aqueous outflow resistance in open angle 
glaucoma 
 
The exact site of aqueous outflow resistance in glaucoma is still unclear and 
continues to be an area of intense study (Tombran-Tink et al., 2008). 
Histological, experimental, and theoretical studies of the aqueous outflow 
pathways point toward the juxtacanalicular region and inner wall of Schlemm’s 
canal as the likely site of highest aqueous outflow resistance. It forms at least 
50% of the aqueous outflow resistance in normal eyes and the bulk of the 
pathologically increased resistance in glaucomatous ones (Johnson and 
Johnson, 2001, Grant, 1963). In the memorable experiment of Morton Grant, he 
tried to find out the point of greatest outflow resistance in the Schlemm’s 
canal.  He dissected the trabecular meshwork in enucleated human eyes so that 
the depth of dissection was correlated with perfusion of the same eye to 
measure outflow facility. Grant used a perfusion pressure so that the IOP is kept 
between 15-25mmHg. There was no change in the outflow resistance until he 
penetrated the inner wall of Schlemm’s canal. He thus found that approximately 
75% of the resistance to aqueous outflow was either at or just proximal to the 
inner wall of the canal in both healthy human eyes and those with open-angle 
glaucoma (Grant, 1963). He concluded that bypassing the proximal resistance 
of the anterior wall of Schlemm’s canal with a technique such as trabeculotomy 
could eliminate ¾ of the aqueous outflow resistance in eyes with glaucoma. 
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1.1.8. Current treatment concepts for glaucoma 
 
Lowering intraocular pressure (IOP) is currently the only option proven to be 
effective to slow or halt the deterioration of visual function in glaucoma 
(Garway-Heath et al., 2015). 
A long time ago, the debate arose on whether to consider a primary surgery for 
open angle glaucoma or to follow the conventional practice pattern of firstly 
offering the medical treatment, and in some cases the laser treatment for 
patients. Medical therapy is still the first line of treatment in the developed world, 
while in poor countries surgery may come as a first treatment option, where non 
compliance to therapy and costs of a long term medical treatment may be 
unaffordable.  Lichter el al did not find a significant benefit from the aggressive 
primary trabeculectomy surgery for open angle glaucoma after 4 years, 
compared with the primary medical treatment (Lichter et al., 2001). In contrast, 
Jay et al (Jay and Murray, 1988) concluded that early operation provides a 
significantly better protection of the visual field. Moreover Hitchings (Hitchings, 
1993) stated that a long period of local medical treatment for glaucoma could be 
a risk factor for failure of filtration glaucoma surgery because of chronic irritation 
to the conjunctiva and the episclera. In concordance, Sherwood et al (Sherwood 
et al., 1989) found a significant increase in the number of macrophages, 
lymphocytes, and fibroblasts in the conjunctiva and Tenon’s capsule in patients 
who received long term glaucoma topical therapy. This may stimulate the 
unwanted excessive healing at the site of surgery. It is known that a healed 
trabeculectomy is a failed one.  
The problem remains to weigh between the potency of different therapeutic 
modalities to halt the progression of glaucoma and the risk of potential 
complications. It can be argued, that the risk of complications is higher for 
surgical procedures than medications. However, the common use of the 
“maximum tolerated medical therapy” results in poor adherence, ocular irritation 
and greater financial burden for the health system.  
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Bylsma (Bylsma, 1999) suggested that if the safety margin of glaucoma surgery 
could be increased significantly without sacrificing efficacy, surgical intervention 
for glaucoma might be considered earlier. 
1.2. Surgical treatment of glaucoma 
Until recently, the surgical options were limited to filtration surgery including 
trabeculectomy or glaucoma drainage devices such as the Ahmed glaucoma 
valve, the Baerveldt implant, or the Molteno implant. Currently, trabeculectomy 
with or without antimetabolites such as 5-fluoruracil or mitomycin-C is still 
considered the gold standard for surgical lowering of intraocular pressure. 
Results of new glaucoma surgical techniques still have to be validated in 
reference to the IOP lowering efficacy and safety of trabeculectomy. 
1.2.1. Trabeculectomy 
Cairns first published a description of trabeculectomy technique 1968 (Cairns, 
1968). Trabeculectomy is designed to divert aqueous from the anterior chamber 
to the subconjunctival space. The success of the procedure depends upon 
aqueous flowing to the subconjunctival space, distributing within the space, and 
being reabsorbed. The main disadvantage of the subconjunctival space as an 
aqueous outflow-rout is that, the resistance to aqueous outflow depends on the 
variations in the wound-healing response of Tenon’s tissue. This makes the 
results highly unpredictable. Antifibrotic agents such as mitomycin-C (Reibaldi 
et al., 2008) and 5-fluoruracil (Koutsonas et al., 2013) have been  introduced to 
modulate the wound healing response (Lama and Fechtner, 2003). However, 
the effect of anti-fibrotic therapy is nearly as unpredictable as the wound-healing 
response itself (Tombran-Tink et al., 2008). 
Trabeculectomy technique has well known problems and complications as well. 
In about up to 30% of cases, trabeculectomy fails to achieve adequate 
intraocular pressure lowering (Jampel et al., 2012). Furthermore, Increased IOP 
is not an uncommon postoperative complication. This usually occurs as a result 
of occlusion of the fistula internally by hemorrhage, fibrin, vitreous incarceration, 
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a plug of iris or retained viscoelastic material. Rarely, increased IOP might be 
the result of a postoperative malignant glaucoma.  
Hypotony due to excessive filtration is another typical complication after filtering 
surgery. Prolonged hypotony can cause visual impairment due to macular folds, 
macular edema or choroidal hemorrhage (Vijaya et al., 2011). Blebitis is a rare 
but potentially sight-threatening complication that can lead to endophthalmitis, if 
not treated appropriately. Also, cataract formation (Jampel et al., 2012) can be 
accelerated after trabeculectomy. Additionally, trabeculectomy necessitates 
longer inpatient period and frequent follow-up visits.(Drake, 1992, Kanski and 
Bowling, 2011) 
 
1.2.2. Non-penetrating glaucoma surgery  
Meanwhile, non-penetrating glaucoma surgery (NPGS; deep sclerectomy and 
viscocanalostomy) has been developed seeking for a better safety compared to 
trabeculectomy. However, the improved safety profile of these procedures 
comes at the expense of worse IOP lowering effect.  
The efficacy of NPGS depends on filtration of aqueous through a trabeculo-
descemet membrane (TDM) into a suprachoroidal scleral lake. 
Viscocanalostomy depends moreover on a local deroofing and viscodilation of 
Schlemm’s canal through injection of viscoelastic substance into two surgically 
created ostia in the canal (Shaarawy et al., 2003).  In the classic 
viscocanalostomy described by Stegmann, the superficial scleral flap has to be 
tightly sutured in order keep the viscoelastic substance in situ and to force 
aqueous percolation into the created sclera lake (Stegmann et al., 1999). 
Sharaawy described a loose suturing of the superficial sclera flap trying to use 
the subconjunctival space as an additional outflow route and thus theoretically 
increasing the chance of success (Shaarawy et al., 2003). 
Nevertheless, insufficient filtration through the TDM is common, and so, 
Nd:YAG laser goniopuncture is often required to open the TDM window, thus 
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converting the procedure from NPGS into a fistulating one (Alp et al., 2010, 
Anand and Pilling, 2010).  
 
1.3. Canaloplasty 
Canaloplasty has been developed on the basis of viscocanalostomy. It aims to 
a more anatomical restoration of aqueous outflow pathway with a notably high 
safety profile. Recent advances in technology have enabled the development of 
a device that allows 360° cannulation of Schlemm’s canal in order to expand the 
entire circumference with viscoelastic and also to allow a suture to be delivered 
within the canal. The function of the suture is to exert centripetal force 
maintaining expansion of the canal. This approach enhances physiologic 
aqueous outflow through the natural pathway in contrast to trabeculectomy 
which relies on an artificial fistula diverting aqueous outflow to the 
subconjunctival space.  
 
 
1.3.1. Surgical technique  
 
Lewis et al (Lewis et al., 2007) first described the technique for canaloplasty. 
Briefly, a one-half thickness scleral flap is dissected. A deep flap is then 
dissected down to a depth very close to the ciliary body/choroid and carefully 
carried forward anteriorly until Schlemm’s canal is unroofed. The ostia of the 
canal are then carefully dissected and viscodilated to allow easy access of the 
microcatheter. The deep flap dissection is then further carried forward into clear 
cornea to expose a small segment of Descemet’s membrane creating a 
trabeculeo-descemetic window. A specially designed microcatheter (iTrack, 
iScience Interventional, Menlo Park, California, USA) is then circumferentially 
introduced into Schlemm’s canal. The beacon tip of the microcatheter is 
illuminated by a laser-diode based microillumination system (iLumin, iScience 
Interventional, Menlo Park, California, USA). A 10-0 polypropylene (Prolene) 
suture is tied to the catheter tip, after the entire canal has been catheterized. 
 16 
 
The catheter is then retracted into the canal in a smooth continuous movement. 
As the tip and the suture are retracted, Healon GV (Advanced Medical Optics, 
Santa Ana, California, USA) is injected every 2 clock hours through an inbuilt 
viscoelastic injector. The polypropylene suture in the canal is tightened, causing 
distention of the trabecular meshwork inwards and further distention of the 
canal. This can be verified intraoperatively using the i-Ultrasound system 
enabling accurate suture tensioning. After satisfactory tightening of the suture 
has been achieved, the deep flap is excised creating a scleral lake. The 
superficial flap is then closed tightly with good tissue apposition to achieve a 
watertight closure.  
 
Canaloplasty is often combined with cataract surgery, which might increase the 
efficacy of the procedure (Lewis et al., 2009, Lewis et al., 2011, Lewis et al., 
2007, Shingleton et al., 2008).  
 
 
1.3.2. IOP lowering mechanisms 
 
Although the exact mechanism of IOP lowering effect of canaloplasty is not 
clearly understood, an improvement of the Schlemm’s canal outflow facility 
seems to be the main mechanism of action. The 360 degree catheterization and 
the viscodilation dissect the septa within the canal and cause a permanent 
dilatation. Tensioning of the canal through the suture keeps it open, so that the 
flow of aqueous can travel into the canal circumferentially, then to the collector 
channels and aqueous veins. It is assumed that it also increases the 
permeability of the trabecular meshwork similarly to pilocarpine (Lewis et al., 
2007). Lewis et al compared the results of canaloplasty with and without 
insertion of a tensioning suture into Schlemm’s canal (Lewis et al., 2007).  
Cases without the suture achieved a mean IOP reduction of 24% after 12 
months, compared to 40% in cases with canal distention. 
The percolation of aqueous through the Descemet window into the scleral lake 
plays an important role for the IOP decrease. An enhanced aqueous humor 
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filtration through the sclera and conjunctive is assumed because of the 
increased conjunctival microcysts formation after canaloplasty (Brusini, 2014). A 
conjunctival bleb can be seen, if the sclera flap is not sutured water-tight. If this 
bleb does not disappear with time, one can assume that the IOP lowering effect 
of the procedure is mediated by the unintended filtration. 
 
The difficulty to determine the exact mechanism of canaloplasty lies in our 
inability to monitor the exact aqueous outflow routes. It has been attempted to 
visualize the aqueous outflow routes through injecting fluorescein in the anterior 
chamber (Benedikt, 1976). Grieshaber et al. injected fluorescein sodium tracer 
directly into the Schlemm’s canal through a microcatheter. The so called 
canalography permits video recording and evaluation of the aqueous outflow 
pathway (Grieshaber et al., 2009). However, since the dye is directly injected 
into the Schlemm’s canal, the aqueous outflow properties of the inner wall of the 
canal cannot be assessed with this technique. The dye is also prone to leak into 
the anterior chamber and the suprachoroidal space rather to completely follow 
the natural outflow route. Recently, Zeppa et al. injected indocyanine green 
(ICG) coupled with a viscoelastic solution using a microcatheter into the 
Schlemm’s canal in 10 patients undergoing canaloplasty. The distribution of the 
dye was monitored with near-infrared light (Zeppa et al., 2016). However, the 
speed and pressure of the injection, the effect of the cannulation and the intra 
operative pressure fluctuation were factors that affected the results. It is still not 
possible to assess the aqueous outflow in vivo. 
 
 
1.3.3. Potential candidates 
 
The most promising results with canaloplasty have been achieved in patients 
with primary open angle glaucoma, pseudoexfoliation glaucoma and pigmentary 
glaucoma (Brusini, 2014). Canaloplasty can also be successfully performed in 
patients with failed trabeculectomy in whom Schlemm’s canal has been left 
undamaged from previous filtrating surgeries (Brusini and Tosoni, 2014). 
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1.3.4. Contraindications 
 
Canaloplasty is contraindicated in patients with angle closure glaucoma 
(although it can be still considered in some patients after a laser or surgical 
iridectomy). Eyes with damaged Schlemm’s canal during previous ocular 
surgery or extensive laser trabeculoplasty with peripheral anterior synechiae are 
not suitable candidates for canaloplasty. Also, ocular hypertension due to an 
increased episcleral venous pressure and other forms of secondary glaucomas 
are contraindications for canaloplasty (Brusini, 2014, Godfrey et al., 2009). 
 
 
1.3.5. Current results 
 
The first comprehensive evaluation of canaloplasty was presented by Lewis et 
al (Lewis et al., 2011). They have included 157 eyes with open angle glaucoma 
in their study. Patients with angle closure and uveitic glaucoma, as well as 
patients who had undergone more than two laser trabeculoplasties were 
excluded. The mean IOP decreased from 23.8 ± 5.0 mmHg on 1.8 ± 0.9 
medications to 15.2 ± 3.5 mmHg on 0.8 ± 0.9 medications. This was a decrease 
of 36.1% of the mean IOP. In 30 eyes canaloplasty was combined with 
phacoemulsification. Phaco-canaloplasty achieved an IOP decrease from 23.5 
± 5.2 mmHg on 1.5 ± 1.0 medications to 13.6 ± 3.6 mmHg on 0.3 ± 0.5 
medications at three years postoperatively representing a 42.1% reduction of 
the mean IOP. However, the IOP lowering effect of the combined procedure 
was not significantly superior to that of the stand alone operation.  
 
In another study, Brusini reported 4 years results of 214 eyes who underwent 
canaloplasty (Brusini, 2014). The mean IOP decreased from a mean of 29.4 ± 
7.9 mmHg under 3.3 ± 0.9 medications preoperatively to 17.0 ± 4.2 mmHg 
under 1.3 ± 1.5 medications postoperatively. However, 17 patients underwent 
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trabeculectomy after 3 to 58 months after canaloplasty because of poor IOP 
control.  
 
Similar results were achieved by Bull et al. in a prospective study which 
included 109 patients with a 3-years follow-up (Bull et al., 2011).  Mean IOP at 
baseline was 23.0 ± 4.3 mmHg under 1.9 ± 0.7 medications which decreased to 
15.1 ± 3.1 mmHg on 0.9 ± 0.9 medications at 3 years postoperatively.  
 
 
1.3.6. Safety   
 
One of the major advantages of canaloplasty is the absence of the usual vision-
threatening complications of filtrating glaucoma surgery, such as choroidal 
detachments, shallow or collapsed anterior chambers, and prolonged 
hypotensive periods (Koerber, 2012). Nevertheless, a series of operative 
difficulties and complications which are specific for canaloplasty have been 
described. Canaloplasty is a surgically challenging technique. It needs a 
relatively long learning curve and special surgical skills when compared to 
trabeculectomy. Unsuccessful circumferential Schlemm’s canal catheterization 
is reported to range between 10% and 26% (Brusini, 2014, Bull et al., 2011, 
Grieshaber et al., 2010c, Lewis et al., 2009, Lewis et al., 2011, Lewis et al., 
2007, Shingleton et al., 2008). This is attributed mostly to surgical inexperience 
or anatomical obstacles such as stenosis of Schlemm’s canal or deviation of the 
microcatheter into the anterior chamber or into a collector channel. Other 
postoperative complications reported in the literature include suture ‘cheese-
wiring through the trabecular meshwork in up to 12%, Descemet’s membrane 
detachment in up to 9.1%,(Brusini, 2014, Grieshaber et al., 2010c, Lewis et al., 
2011, Lewis et al., 2007) and hyphema in up to 70% (Bull et al., 2011, 
Grieshaber et al., 2010c, Lewis et al., 2009, Lewis et al., 2011, Shingleton et al., 
2008) Hyphema is generally transient and resolves within a week in the majority 
of cases.  
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1.4. Aim of work 
Most published reports assessed the short- and (Brusini, 2014, Bull et al., 2011, 
Grieshaber et al., 2011a, Koerber, 2012, Lewis et al., 2011, Shingleton et al., 
2008) midterm results of canaloplasty (Shingleton et al., 2008, Grieshaber et al., 
2011a, Koerber, 2012). In the first study of this thesis, we discuss the long-term 
safety and efficacy of canaloplasty. This is the longest follow up for canaloplasty 
in the literature. 
The main intraoperative complications of canaloplasty are the failure to perform 
a 360° catheterization of Schlemm’s canal or the inability to introduce a 
tensioning suture within the canal. In the second study of this thesis, we studied 
the conversion of canaloplasty into trabeculotomy as a method to deal with 
these complications.  
 
2. Results and Discussion 
 
2.1. [Treatment efficacy and safety of canaloplasty for open-angle 
glaucoma after 5 years. (Voykov B., Blumenstock G, Leitritz 
MA, Dimopoulos S, Alnahrawy O., published in Clin Exp 
Ophthalmol)](Voykov et al., 2015a) 
 
 
Introduction 
Circumferential viscodilation and tensioning of Schlemm’s canal with a flexible 
microcatheter (canaloplasty) is one of the recent advances in non-penetrating 
glaucoma surgery. It seeks to improve the outflow of aqueous humor through 
the trabecular meshwork and a Descemet window into and around Schlemm 
canal and out through the collector channel system. (Shingleton et al., 2008) 
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Thus, in theory, canaloplasty restores the trabeculocanalicular outflow pathway. 
However, suture tensioning of Schlemm canal may also alter the anatomy of the 
trabecular meshwork (Brusini, 2014, Grieshaber et al., 2010b). It has been 
proposed that this alteration might offer mild, late reduction of intraocular 
pressure (IOP) remotely after surgery (Grieshaber et al., 2010b). Another 
possible outflow mechanism in canaloplasty involves the intra-scleral space 
created after excision of the deep scleral flap. From here, an enhanced 
aqueous humor filtration across the sclera and conjunctiva has been observed 
(Mastropasqua et al., 2012). The exact contribution of each mechanism is not 
clear. Nevertheless, published data demonstrate good efficacy and safety of 
canaloplasty in the short and mid-term (Grieshaber et al., 2010b, Lewis et al., 
2011, Bull et al., 2011, Brusini, 2014, Lewis et al., 2009, Lewis et al., 2007, 
Shingleton et al., 2008, Mastropasqua et al., 2012). However, anatomical 
changes in the trabecular meshwork and/or the intra-scleral space might be 
causes of failure in the long-term as seen in the course of non-penetrating deep 
sclerectomy for example (Roy and Mermoud, 2006). That has aroused our 
interest to investigate, if there is a decline of efficacy of canaloplasty in 
controlling open-angle glaucoma in the long-term. In the present study, the 
safety and efficacy of canaloplasty in the treatment of adult patients with open-
angle glaucoma (OAG) were investigated. 
 
Patients and Methods 
In this study, all medical records of consecutive patients who underwent 
canaloplasty after January 2009 in the Centre for Ophthalmology at the 
University Hospital Tübingen were reviewed. Inclusion criteria included 
diagnosis of insufficiently controlled open-angle glaucoma (OAG) on maximal 
tolerated medical therapy and a minimum follow-up of five years. Exclusion 
criteria included all other forms of glaucoma and previous intraocular surgery 
except phacoemulsification. Previous cyclophotocoagulation was not an 
exclusion criterion. Patients that underwent filtration surgery were considered as 
 22 
 
failure. Written informed consent was obtained after a comprehensive 
discussion of the experimental nature of the procedure from all patients before 
surgery. We documented age at surgery, gender, type of glaucoma, 
preoperative and postoperative best corrected visual acuity (BCVA), intraocular 
pressure, number of glaucoma medications, lens status, and intra- and 
postoperative complications for each patient. Combination glaucoma 
medications were enumerated as individual medications. 
This work adhered to the tenets of the Declaration of Helsinki and the 
requirements of the local institutional review board. 
 
Operative technique 
The surgical procedure followed the technique described by Lewis et al  (Lewis 
et al., 2007). Briefly, after conjunctival dissection at the 12 o’clock limbus, a 
non-penetrating two-flap dissection of the sclera was prepared to expose 
Schlemm’s canal. The iTrack-microcatheter (Ellex iScience, Inc., Fremont, CA, 
USA) was used to dilate the full circumference of the canal. Dilation was 
facilitated by the injection of 1.4% sodium hyaluronate (Healon GV, Advanced 
Medical Optics, Inc., Santa Ana, CA). After circumferential catheterisation, a 10-
0 Prolene suture (Ethicon, Inc., Somerville, NJ) was tied to the microcatheter tip 
and the device was withdrawn, pulling the suture into the canal. Then, the 
suture was cut from the microcatheter and the two ends were tightened to 
distend the trabecular meshwork inward. The deep flap was excised and the 
superficial flap and conjunctiva were sutured watertight. 
 
Efficacy 
The success of surgical outcome was defined as complete when no additional 
medication was required or qualified when additional medication was required 
to achieve the specific IOP definition. Success was also defined at two IOP cut‐
off points (IOP ≤ 21 mm Hg and IOP ≤ 18 mm Hg, and at least a 25% reduction 
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from baseline). These cut-off points were used in order to allow comparison with 
previous studies on canaloplasty. Three specific time points were used to define 
success outcomes: at one, three and five years after surgery.  
 
Statistical analysis 
Continuous data were compared by analysis of variance (Student’s t-test). 
Contingency table analysis and logistic regression were used to evaluate 
factors potentially associated with success and failure. Values for p of less than 
0.05 were considered to reflect significant differences. The statistical analysis 
was performed with the JMP 11.0 statistical package (SAS Institute Inc., Cary, 
NC, USA).   
 
Results 
Demographics 
Canaloplasty was performed in 60 eyes in the observed period. Of those, 20 
had a follow up of at least five years and fulfilled the inclusion criteria. Only 
these eyes were included for further analysis. Demographic characteristics of 
the patients included are summarised in table 1. None of the eyes underwent 
canaloplasty combined with cataract surgery. Two eyes had undergone a single 
transscleral cyclophotocoagulation three and five years before canaloplasty.  
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 Demographic  Value  
 General    
 Eyes, n (%)  20  
 Right  7 (35)  
 Left  13 (65)  
 Women, n (%)  11 (55)  
 Men, n (%)  9 (45)  
 Age (y)    
 Mean ± SD  60 ± 11  
 Range  44-82  
 Diagnosis, n (%)    
 POAG  15 (75)  
 Pigmentary glaucoma  2 (10)  
 Exfoliation glaucoma  2 (10)  
 Uveitic glaucoma  1 (5)  
 Baseline    
 IOP, mm Hg    
 Mean ± SD  25.7 ± 6.6  
 Mean medications ± SD  3.4 ± 0.5  
 Previous glaucoma surgery, n (%)  2 (10)  
 Transscleral cyclophotocoagulation  2 (10)  
 Phakic, n (%)  14 (70)  
 Pseudophakic, n (%)  6 (30)  
 BCVA (LogMAR) ± SD  0.27 ± 0.35  
Table 1. Patients’ demographics. 
IOP and Antiglaucoma Medications 
Figures 2 and 3 show the efficacy results.  
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Figure (2)  Scatter diagram of pre and postoperative IOP at 5 years with different cut off points (≤16, ≤18 
and ≤21 mmHg). 
 
The mean IOP decreased from 25.7 ± 6.6 mmHg (standard deviation [SD]) at 
baseline to 15.5 ± 3.8 mmHg (n=19) at one year (p<0.001), 15.1 ± 4.4 mmHg 
(n=18) at three years (p<0.001), and 14.2 ± 3.4 mmHg (n=18) at five years 
(p<0.001). The differences between one, three and five years were not 
significant. Mean number of medications decreased from 3.4 ± 0.5 at baseline 
to 1.5 ± 1.6 at one year (p<0.001), 1.6 ± 1.4 at three years (p<0.001), and 1.7 ± 
1.3 at five years (p<0.001).  
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Figure (3) Mean number of medications at different time points. 
 
Visual acuity 
BCVA decreased from 0.27 logMAR at baseline to 0.28 logMAR at three years 
(p=0.58) and 0.47 logMAR at five years (p=0.06).  
 
Success 
Success results for the different time periods and definitions are presented in 
table 2.  
Complete and qualified success rates were 10% and 95% for the softest 
criterion (IOP ≤ 21 mmHg), respectively. The rates were 5% and 75% for the 
strictest criterion (≤18 mm Hg and ≥25% IOP reduction). 
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Success rate 
% 
 
 
  1 year  
n=19 
 
3 years 
n=18  
 
5 years 
n=18  
 
 Complete success       
 ≤21 mm Hg 37  28  10  
 ≤21 mm Hg and ≥25% IOP 
reduction* 
26  22  5 
 
 ≤18 mm Hg 37  28  10  
 ≤18 mm Hg and ≥25% IOP 
reduction* 
26  22  5 
 
 Qualified success       
 ≤21 mm Hg 90  89  95  
 ≤21 mm Hg and ≥25% IOP 
reduction* 
73  66  75 
 
 ≤18 mm Hg 79  82  95  
 ≤18 mm Hg and ≥25% IOP 
reduction* 
68  66  75 
 
Table 2. Success results at 1, 3 and 5 years.  
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Complications 
Complications are presented in table 3. The overall complication rate was low.  
 Complication    
 Early postoperative, n (%)    
 Transient hypotony  1 (5)  
 Microhyphema  5 (25)  
 Macrohyphema  2 (10)  
 Transient IOP elevation  0 (0)  
 Detachment Descemet membrane  0 (0)  
 Late postoperative, n (%)    
 Endophthalmitis  0 (0)  
 POAG = primary open-angle glaucoma; IOP = intraocular pressure; 
Microhyphema = <1 mm layered blood in anterior chamber; Macrohyphema = 
≥1 mm layered blood in anterior chamber 
 
Table 3. Ocular-related surgical and postsurgical complications. 
 
The most common early postoperative complication was hyphema, which was 
observed in 7 (35%) eyes. Transient hypotony was observed in one (5%) eye in 
the early postoperative phase, which resolved spontaneously within one week 
after surgery. We did not observe any case of endophthalmitis or other sight-
threatening complications. We did not see any cases of dislocation of the 
Prolene suture after five years.   
 
Further surgery 
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Thirteen (65%) eyes needed further surgery because of insufficient IOP control 
during the follow-up period of 5 years. Median time to further surgery was 24 
months (95%-confidence interval 1-51 months). One eye was treated with a 
single transscleral cyclophotocoagulation. In 12 eyes micro-invasive suture 
trabeculotomy was performed first, followed by trabeculectomy with mitomycin 
C in two eyes and TSCPC in another four.   
 
Discussion 
Canaloplasty is one of the recent advances in non-penetrating glaucoma 
surgery. There is increasing evidence for the efficacy and safety of canaloplasty 
in the literature (Bruggemann et al., 2013, Bull et al., 2011, Grieshaber, 2012, 
Grieshaber et al., 2010a, Grieshaber et al., 2010b, Koerber, 2011, Lewis et al., 
2011, Matlach et al., 2013, Tetz et al., 2013, Brusini, 2014). In the current study, 
we investigated the long-term safety and efficacy of canaloplasty in the 
treatment of OAG. Our results show that the efficacy of the procedure slowly 
decreases in time. We did not observe any case of endophthalmitis or other 
sight-threatening complications. 
  
In the current study, a lowering of the mean IOP was achieved from 25.7 ± 6.6 
mmHg on 3.4 ± 0.5 medications to 15.1 ± 4.4 mmHg on 1.6 ± 1.4 medications 
after three years. The complete and qualified success rates for IOP ≤ 21 mmHg 
were 28% and 89%, after three years, respectively. Our results compare well to 
previously reported studies. Lewis et al. demonstrated a significant reduction in 
the mean IOP from 23.5 ± 4.5 mmHg on 1.9 ± 0.8 medications at baseline to 
15.5 ± 3.5 mmHg on 0.9 ± 0.9 medications after three years. The reported 
complete success rate in a group of patients with successful suture implantation 
without cataract surgery was 40.4% for IOP ≤ 21 mmHg, and 95.5% had 
qualified success at three years (Lewis et al., 2011). Bull et al. reported similar 
results in a group of 82 eyes with canaloplasty alone. They achieved a lowering 
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of mean IOP from 23.0 ± 4.3 mmHg on 1.9 ± 0.7 medications to 15.1 ± 3.1 
mmHg on 0.9 ± 0.9 medications at three years.(Bull et al., 2011) Complete and 
qualified success for IOP ≤ 21 mmHg was achieved in 40.5% and 98.6% of the 
eyes at three years, respectively (Bull et al., 2011).  Grieshaber et al. 
demonstrated similar efficacy rates for canaloplasty in black African patients 
after three years (Grieshaber et al., 2010b). Brusini reported a complete 
success of 44.8% and a qualified success of 86.2% for IOP ≤ 21 mmHg 
(Brusini, 2014). The complete success rates in our study were lower compared 
to the above studies. A possible explanation for this is a learning curve effect 
since we included some of our first canaloplasty patients in the study. Another 
possibility is that IOP in our patient population was generally more difficult to 
control compared to the studies of Lewis et al. and Bull et al. since the number 
of baseline medications in the current study was notably higher (3.4 vs 1.9 for 
the above mentioned studies). (Bull et al., 2011, Lewis et al., 2011). After five 
years, the majority of eyes required additional medication for IOP control. The 
complete and qualified success rates were 10% and 95%, respectively. The 
mean IOP was 14.2 ± 3.4 mmHg on 1.7 ± 1.3 medications. During the follow up, 
13 (65%) eyes needed further surgery because of insufficient IOP control. In 12 
of those eyes micro-invasive suture trabeculotomy (MIST) was performed as 
previously described (Voykov et al., 2014).  
Although we did not compare canaloplasty and standard filtration surgery in the 
current study, based on our and literature results, canaloplasty has a lower 
efficacy of both (Ayyala et al., 2011, Matlach et al., 2015, Matlach et al., 2013, 
Rulli et al., 2013, Schoenberg et al., 2013, Thederan et al., 2014).  
The complication rate after canaloplasty was very low in the current study and 
compared favourably to previous studies (Brusini, 2014, Bull et al., 2011, Lewis 
et al., 2011). Hyphema was the most common complication which occurred in 
one third of the eyes. In a study by Grieshaber et al., microhyphema on the first 
postoperative day was found to be predictive of success (IOP lower than 16 
mmHg without medications) after a mean follow-up of 20.6 months (Grieshaber 
et al., 2011b). In our study, microhyphema was not a positive prognostic 
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indicator. However, comparison between both studies is difficult, because of the 
different definitions of success and microhyphema, which was defined as less 
than 1 mm layered blood in the present study and had no such strict definition in 
the study by Grieshaber et al  “reported range 1-2.5 mm” (Grieshaber et al., 
2011b). The frequency of microhyphema (85.1%) appears to be quite high in 
the latter study compared to the majority of published results, including ours 
(Bull et al., 2011, Lewis et al., 2011). We did not observe any sight threatening 
complications during the follow up of five years.  
Of the studied factors, including age, gender, number of preoperative 
medications, baseline IOP, and hyphema, none were predictive for success in 
our study. Further studies, designed to evaluate the indicators for success and 
failure, are necessary for optimising preoperative patient selection.  
 
Limitations of the study include the small sample size as well as a possible 
selection bias adherent to the retrospective design. Further prospective studies 
with a larger number of cases are warranted to evaluate the long term safety 
and efficacy of the procedure as well as specific risk factors for failure.  
In conclusion, our results show that canaloplasty lowered IOP in this series of 
patients but many patients (65%) needed further surgery to control IOP. We did 
not observe any sight threatening complications of the procedure.     
 
2.2. [Exit strategies in canaloplasty: intraoperative conversion 
into 180-degree trabeculotomy or 360-degree trabeculotomy in 
cases of unsuccessful catheterisation of Schlemm’s canal: 
influence of degree of canal cleavage (Alnahrawy O, Blumenstock 
G, Ziemssen F, Szurman P, Leitritz MA, Dimopoulos S, Voykov B., 
published in Graefes Arch Clin Exp Ophthalmol)](Alnahrawy et al., 
2015) 
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Introduction: 
Canaloplasty is a novel surgical technique that aims to lower IOP using a non-
penetrating approach through circumferential catheterisation of SC and 
placement of tension suture to restore natural aqueous outflow pathways. This 
obviates the need of external fistulisation which has more frequent early and 
late postoperative bleb related complications (Bettin and Di Matteo, 2013, 
Bruggemann et al., 2013, Lewis et al., 2011, Lewis et al., 2007, Shingleton et 
al., 2008). But what if catheterisation of SC fails or the placement of a tension 
suture is unsuccessful? Both scenarios are challenging surgical problems in the 
course of surgery, occurring in 10% to 26% of eyes undergoing canaloplasty 
surgery (Brusini, 2014, Bull et al., 2011, Grieshaber et al., 2010c, Lewis et al., 
2009, Lewis et al., 2011, Lewis et al., 2007, Shingleton et al., 2008). Suture 
cheese wiring through the trabecular meshwork (TM) is another complication, 
which precludes suture placement (Brusini, 2014, Grieshaber et al., 2010c, 
Lewis et al., 2009, Lewis et al., 2011). Growing surgical experience helps to 
increase the technical success; however, anatomical obstacles such as SC 
stenosis remain difficult to overcome (Koerber, 2012, Lewis et al., 2009, Lewis 
et al., 2011, Lewis et al., 2007).  Meanwhile different surgical “escape” 
strategies such as viscocanalostomy and deep sclerectomy have been 
described, but no gold standard has yet been established (Bull et al., 2011, 
Lewis et al., 2009, Lewis et al., 2011).  Table 4 (Bruggemann et al., 2013, 
Brusini, 2014, Bull et al., 2011, Grieshaber et al., 2010c, Grieshaber et al., 
2013, Lewis et al., 2009, Lewis et al., 2011, Lewis et al., 2007, Shingleton et al., 
2008) shows the literature overview of the currently documented surgical and 
postsurgical difficulties/complications in canaloplasty. 
In this study the safety and efficacy of intraoperative conversion of unsuccessful 
canaloplasty into 180 degree metal or 360 degree suture trabeculotomy were 
investigated. 
 
Patients and methods: 
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A total of 183 eyes that underwent canaloplasty surgery in the Centre for 
Ophthalmology, University Hospital Tübingen from November 2008 to July 2013 
were studied. 122 eyes were operated using the Glaucolight (DORC 
International, Zuidland, The Netherlands)  microcatheter, and 61 eyes using the 
iTrack (iScience Interventional, Menlo Park, CA), microcatheter. 
In this retrospective case series 35 patients with primary open angle glaucoma, 
pseudoexfoliative or pigmentary glaucoma, with uncontrolled IOP, who 
underwent intraoperative conversion of canaloplasty into 180 degree metal or 
360 degree suture trabeculotomy were included. 
 
Eyes were divided into two groups: Group A comprised 17 eyes, which had 
unsuccessful circumferential SC catheterisation because of intracanalicular 
stenosis or catheter deviation into a collector channel or into the anterior 
chamber. These eyes were converted into 180 degree metal trabeculotomy. 
Group B comprised 18 eyes, which had a cheese wiring or partial suture or 
microcatheter extrusion through the TM during withdrawal. In this case the 
procedure was converted into 360 degree trabeculotomy.   
Patients with other forms of glaucoma or with previous glaucoma surgery were 
excluded. None of the patients had a simultaneous lens operation in both 
groups.  Success was defined as the percentage of eyes that reached a target 
IOP ≤ 21mmHg or IOP ≤ 21 mm Hg and at least 25% reduction from baseline. 
Success was classified as complete when no glaucoma medications were 
needed postoperatively, and qualified when one or more glaucoma medications 
were still used.  
This work adhered to the tenets of the Declaration of Helsinki. According to 
German legislation and the requirements of the local IRB, completely 
anonymised data was used for this study. 
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Complication (%)  
 Unsuccessful 
catheterisation 
or 
tension-suture 
placement 
 
Cheese 
wiring 
through 
TM 
 Hyphema  
IOP 
increase 
 
 Hypotony  Choroidal effusion 
Descemet 
detachment 
 
Brüggemann et al. 
2013(Bruggemann 
et al., 2013) 
n.a.  n.a.  26.7  n.a.  6.7  n.a. 6.7  
Brusini 
2014(Brusini, 
2014) 
16.4  0.9  21.9  5.6  9.8  none 5.1  
Bull et al. 
2011(Bull et al., 
2011) 
11.1  n.a.  18.3  7.3  none  none 3.7  
Grieshaber et al. 
2010(Grieshaber 
et al., 2010c) 
none  2.2  27.8  4.4  none  none 2.2  
Grieshaber et al. 
2013(Grieshaber 
et al., 2013) 
n.a.  n.a.  85.1  n.a.  n.a.  n.a. n.a.  
Lewis et al. 
2007(Lewis et al., 
2007) 
21.3  1.1  3.2  3.2  1.1  1.1 1.1  
Lewis et al. 
2009(Lewis et al., 
2009) 
15  1.6  15.8  10.3  0.8  n.a. 1.6  
Lewis et al. 
2011(Lewis et al., 
2011) 
15.3  1.9  22.3  12.8  0.6  n.a. 3.2  
Shingelton et al. 
2008(Shingleton 
et al., 2008) 
26  none  33.6  n.a.  none  n.a. 1.9  
Table 4.  Literature overview of documented surgical and postsurgical complications in canaloplasty (n.a. 
= not available, TM = trabecular meshwork)  
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Surgical technique: 
The canaloplasty surgical procedure followed the technique described by Lewis 
et al (Lewis et al., 2007). Briefly; a two-flap dissection was carried out until SC 
was deroofed. The two ostia of the canal were dilated with high molecular 
weight hyaluronic acid (Healon GV), followed by an attempt to circumferentially 
introduce a microcatheter into the SC. The iTrack (iScience Interventional, 
Menlo Park, CA), or the Glaucolight microcatheter (DORC International, 
Zuidland, The Netherlands) were used. If this attempt failed, a Neuhann U-
shaped trabeculotome (Geuder, Heidelberg, Germany) was introduced into SC 
through about 90° circumference and its tip was swung gently into the anterior 
chamber cleaving the TM once superotemporally and again superonasally 
completing a trabeculotomy of maximum 180 degree (group A) following the 
original trabeculotomy technique described by Harms and Dannheim (Harms 
and Dannheim, 1970)  
If successful 360 degree catheterisation was achieved, but tension suture could 
not be placed because of cheese wiring or partial suture extrusion through the 
TM (group B), then the suture was retrieved cleaving the entire circumference of 
SC and thus creating a 360 degree trabeculotomy. The operation was then 
completed identically for both groups with excision of the deep scleral flap and 
watertight suturing of the superficial flap. All patients received postoperative 
local treatment with antibiotic and steroid eye drops over two weeks. Pilocarpin 
1% was instilled for 4-6 weeks to hinder synechia formation at the iris base. 
 
Outcome and Statistical analysis: 
Main outcome measures included IOP, number of glaucoma medications, visual 
acuity and success after 6- and 12-month follow-up. The data record for each 
eye included patient age at surgery, gender, glaucoma type, surgical procedure, 
IOP, glaucoma medication, visual acuity, possible complications and 
postoperative interventions. For combination glaucoma medications, the single 
active ingredients were enumerated. 
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For statistical analysis, chi-squared test, Fisher’s exact test, and Wilcoxon rank-
sum test were performed with the JMP 11.0 statistical package (SAS Institute 
Inc., Cary, NC, USA). Values for p of less than 0.05 were considered to reflect 
significant differences.  
 
Results: 
Demographic data for both groups are shown in table 5. There were no 
significant differences in patients’ gender, mean age, lens status, aetiology of 
OAG or logMAR of best corrected visual acuity (BCVA) between both groups 
preoperatively.  
Canaloplasty was attempted with the Glaucolight microcatheter in 15 eyes and 
with the iTrack microcatheter in 2 eyes in group A. In all eyes of group B, the 
Glaucolight microcatheter was used. 
Mean BCVA changed from 0.09±0.15 and 0.31±0.52 at baseline to 0.17±0.35 
and 0.29±0.3 at 12 months postoperatively for group A and group B, 
respectively. These changes were not statistically significant.  
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 Demographic data       
  180° 
Trabeculotomy  
 360° 
Trabeculotomy  
 p-
value 
 
 General       
 Eyes, n 17  18    
 gender     0.44  
 Women, n (%) 14(82)  12(67)  -  
 Men, n (%) 3(18)  6(33)  -  
 Age (y)       
 Mean ± SD 62±13  59 ± 16  0.52  
 Range 44-79  24-82    
 Diagnosis, n      0.57  
 POAG 15  13  -  
 Pigmentary dispersion 
glaucoma 
0  2  -  
 Exfoliation glaucoma 2  3  -  
 Phakic, n (%) 12(71)  16(94)  0.23  
 Pseudophakic, n (%) 5(29)  1(6)  0.09  
 Preoperative BCVA (log 
MAR, mean ± SD) 
0.31±0.15  0.09±0.52  0.14  
 POAG = primary open-angle glaucoma;  BCVA= Best Corrected Visual Acuity; log MAR= Mean 
logarithm of the minimal angle of resolution 
 
Table 5. Patients’ demographics. 
 
Table 6 shows the median values of pre- and postoperative IOP and number of 
glaucoma medications in both groups at 1, 6 and 12 months.  
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              180°  
Trabeculotomy  
          360° 
Trabeculotomy  
  
     
  
 
n Median IOP 
(range) 
 Median number 
of medications 
(range) 
 n Median IOP 
(range) 
 Median number of 
medications 
(range) 
 Baseline 17 22 (16-34)  4 (2-4)  18 22 (15-48)  3 (1-4) 
 Postoperative 
follow-up 
         
 1 Month 17 12 (3-26)  0 (0-3)  18 14 (11-38)  0 (0-4) 
 6 Months 16 15 (4-23)   0 (0-3)  15 13 (10-22)  1 (0-4) 
 12 Months 15 14 (8-27)  2 (0-4)  10 14.5 (9-21)  1 (0-3) 
   
 
  
Table 6. Outcome measures. IOP in mmHg; Number of glaucoma medications 
 
A significant IOP reduction of 36% has been achieved in group A, from 
22.0mmHg (ranging from 16 to 34 mmHg) at baseline to 15.0mmHg (ranging 
from 9 to 21mmHg) at 12 months. In group B, IOP reduced from 22.0mmHg 
(ranging from 15 to 48mmHg) at baseline to 14.5mmHg (ranging from 8 to 
21mmHg) at 12 months representing 34% reduction. 
The median number of glaucoma medications decreased significantly by half in 
group A and by two thirds in group B at 12 months.  
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Figure. 4 Boxplot diagram showing IOP distribution at different time intervals. The whiskers indicate 
minimum and maximum values; the length of the boxes represents the interquartile range, i.e., the middle 
50 % of the data. 180° indicates trabeculotomy degree in group A, and 360° the trabeculotomy degree in 
group B. 
 
The overall success results at 6 and 12 months for both groups are shown in 
Table 7. There were no statistically significant differences between groups A 
and B regarding success results at all time points. 
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   Success Rate (%)   
   180° 
Trabeculotomy  
   360° 
Trabeculotomy  
 
  
  6 
Months 
(n=16) 
 12 
Months 
(n=15) 
 6 
Months 
(n=15) 
 12 
Months 
(n=10) 
 
 Complete success         
 ≤21 mm Hg 62.5   40   40   50  
 ≤21 mm Hg and ≥25% IOP 
reduction* 
56.3  33.3  40   40  
 Qualified success         
 ≤21 mm Hg 93.8   86.7  86.7  80  
 ≤21 mm Hg and ≥25% IOP 
reduction* 
75  60  66.7  60  
 *Reduction from maximum baseline IOP   
Table 7. Success results at 6 and 12 months. All differences between both groups were not statistically 
significant. 
 
Complications: 
Operative and postoperative complications are summarized in Table 8. One eye 
in group A had a trabeculodescemet’s membrane perforation, however it was 
small and the operation could be continued as previously described. The same 
eye had a presumed cyclodialysis with transient hypotony in the first 
postoperative week, but IOP increased above 6mmHg in all next follow-up 
visits.  
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    Complications n (%)   
 
 1180°Trabeculotomy 
 
360°Trabeculotomy 
  
 
   
TDM rupture 
 
1 (6%) 
  
0 
  
 
 Possible 
cyclo/iridodialysis 1 (6%) 
 0   
 Microhyphema 8 (47%)  8 (44%)   
 Macrohyphema 5 (29%)  6(33%)   
 Transient hypotony 2 (12%)  3(17%)   
 Transient IOP elevation 0  2(11%)   
Table 8. Operative and postoperative complications. (TDM = trabeculodescemet membrane.) All 
differences between both groups were not statistically significant. 
 
Two eyes in group A and three eyes in group B showed a transient 
postoperative hypotony (IOP ≤5mmHg) which normalised spontaneously within 
the first week. Transient IOP elevation occurred in two eyes in group B and 
could be rapidly controlled with medical treatment. 
Persistent IOP elevation or frequent IOP spikes >21mmHg were recorded in 
one eye at 6 months and one eye at 12 months in group A, and in two eyes at 6 
months in group B. Three eyes underwent transscleral cyclophotocoagulation 
and a total of four eyes were ultimately considered to have failure at mentioned 
time points. None of the postoperative complications was significantly 
associated with a specific risk of failure. No serious complications, such as 
endophthalmitis, aggressive iridocyclitis, malignant glaucoma or loss of vision 
were observed in both groups. 
  
Discussion: 
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Canaloplasty is a novel procedure that aims to improve the physiological 
aqueous outflow, while avoiding the problem of conjunctival scarring related to 
bleb dependent operations. However, the advent of novel techniques usually 
invites new complications, which need to be dealt with. The current study 
investigates a new approach to deal with two challenging problems at different 
stages in the course of canaloplasty surgery. In our series, converting eyes with 
unsuccessful circumferential catheterisation of SC into 180 degree 
trabeculotomy, and eyes with suture cheese wiring through the trabecular 
meshwork into 360 degree trabeculotomy achieved a significant and sustained 
IOP control with a high safety profile over one year.  
Brusini considered a conversion into deep sclerectomy or viscocanalostomy as 
his backup alternative for those eyes with unsuccessful SC catheterisation or 
impossible suture placement. 
In addition, Lewis et al. and Bull et al. completed the surgery in such eyes 
performing viscocanalostomy. However, no results have yet been published for 
these eyes (Brusini, 2014). Of course, deep sclerectomy or viscocanalostomy 
can be alternative approaches if the anterior chamber has not been 
compromised. However, in the case of cheese wiring through the trabecular 
meshwork during the withdrawal of the microcatheter, a 360-degree 
trabeculotomy is automatically produced.  
 
 
  
Deep sclerectomy with or without implant and viscocanalostomy have shown 
effective IOP control with fewer complications in naïve eyes compared to 
trabeculectomy; however Nd:YAG laser goniopuncture is often required after 
both procedures due to the frequent insufficient filtration through the 
trabeculodescemet’s membrane (Alp et al., 2010, Anand and Pilling, 2010, 
David et al., 2008, Hamel et al., 2001, Lachkar et al., 2004, Mendrinos et al., 
2008, Shaarawy et al., 2001, Shaarawy and Mermoud, 2005, Stegmann et al., 
1999). Furthermore, a significantly superior efficacy of canaloplasty in 
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comparison to viscocanalostomy (fellow eye of the same patient) was 
demonstrated by Koerber (Koerber, 2012).  
We tried a different treatment algorithm in eyes with difficult catheterisation and 
converted the procedure into trabeculotomy. Ab-externo trabeculotomy is a 
popular non-penetrating option in the treatment of adult OAG (Harms and 
Dannheim, 1970). Its effectiveness in controlling IOP by lowering the aqueous 
outflow resistance through cleaving the TM has been reported in the literature 
(Chihara et al., 1993, Chin et al., 2012, Iwaki et al., 1991, Schwenn and Grehn, 
1995, Tanihara et al., 1993, Tanito et al., 2002a, Wada et al., 1994). Suture 
trabeculotomy was first described by Smith in 1960, refined by Beck and Lynch 
in 1995 and Chin et al. in 2012 to involve the entire circumference of SC (Beck 
and Lynch, 1995, Chin et al., 2012, Smith, 1960). Girkin et al. and Dao et al. 
used the iTrak microcatheter to achieve a 360 degree trabeculotomy with good 
results in congenital glaucoma (Dao et al., 2013, Girkin et al., 2012). 
Theoretically, a procedure that opens the entire circumference of SC is 
expected to achieve a better IOP control than a 180 degree technique does 
(Chin et al., 2012). This, however, is not seen in our series. The differences 
between groups A and B regarding IOP reduction and number of postoperative 
glaucoma medications were not statistically significant. We cannot rule out that 
the anatomic differences hindering successful catheterisation in group A were 
associated with a different patient profile. 
Although it is difficult to compare between different studies because of different 
techniques, populations and success criteria, our results compare well to 
viscocanalostomy, which is the most frequently described alternative to 
uncompleted canaloplasty (Bull et al., 2011, Lewis et al., 2009, Lewis et al., 
2011). In our series, a complete success of 40% and 50%, and a qualified 
success of 86.7% and 80% at 12 months were achieved in group A and group 
B, respectively. Using the same definition of success, viscocanalostomy results 
showed a complete success rate ranging from 21.4% to 59% and a qualified 
success ranging from 71% to 88% (Luke et al., 2003, Moradian et al., 2013, 
O'Brart et al., 2002, Sunaric-Megevand and Leuenberger, 2001). Furthermore, 
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canaloplasty studies that included patients with IOP baseline similar to our case 
series, showed an IOP lowering effect and a medication reduction highly 
compatible with our result (Bull et al., 2011, Lewis et al., 2007, Shingleton et al., 
2008). 
Complications reported in the current study were infrequent and temporary. 
Hyphema was the most common postoperative complication , as it is related to 
surgery of SC (Dannheim and Harms, 1969). There was no association 
between the amount of blood and the extent of SC tearing.  
IOP fluctuation is a reported complication after trabeculotomy; however, we 
observed a relatively stable IOP postoperatively, with an overall low rate of 
transient IOP elevation or hypotony (Tanihara et al., 1993, Tanito et al., 2002b). 
It should be noted that of all 35 eyes included in the current study, canaloplasty 
had been attempted with the Glaucolight device in 33 eyes and with iTrack in 2 
eyes. In our opinion, this difference is due to the greater stiffness of the iTrack 
device, which allows an easier catheterisation of SC.  
 
Limitations of this study include the short follow-up, small sample size as well as 
the possible selection bias adherent to the retrospective design. Further 
prospective studies with a larger number of cases and longer follow-up would 
be necessary to evaluate the long term safety and efficacy of the procedure as 
well as specific risk factors for failure.  
In conclusion, the increasing popularity of canaloplasty necessitates new 
strategies to deal with its complications. The currently described approach 
showed a promising IOP control with a high safety profile after one year and 
could be considered in cases of unsuccessful canaloplasty surgery. 
All authors have no affiliations with or involvement in any organization or entity 
with any financial or non-financial interest in the subject matter or materials 
discussed in this manuscript. 
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3. Summary 
Canaloplasty has widened our treatment options for glaucoma. The bleb 
avoiding nature of the procedure results in a high safety profile. Canaloplasty 
allows also a rapid recovery after surgery. It can therefore, be offered for 
selected glaucoma patients even early in the course of the disease.  
This work aimed to assess the long term safety and efficacy of canaloplasty in 
the treatment of open angle glaucoma. The procedure was moderately 
successful in lowering the IOP in the long-term. Additional topical anti-glaucoma 
medications were necessary to achieve satisfactory IOP control over time. 
Ultimately, more than half of operated eyes had to undergo a second surgery to 
keep the IOP within satisfactory levels after 5 years. However, it should be 
considered, that no procedure can guarantee permanent IOP control. 
Therefore, canaloplasty can be used to gain time before further surgery 
becomes necessary. We consider canaloplasty as a part of a so-called triple 
escalating glaucoma treatment: canaloplasty followed first by MIST and then by 
trabeculectomy (Voykov et al., 2015b). 
Canaloplasty, however, is a surgically challenging procedure. Catheterisation of 
Schlemm’s canal is not always possible. Surgical experience, individual 
anatomical variations and the catheter type/rigidity used are important variables 
that determine the success of the operative technique. In the second study, we 
analyzed two possible “escape” strategies in cases of catheterisation failure or 
cheese wiring of the prolene suture through the trabecular meshwork. Our 
results showed that converting the procedure into 180° or 360° trabeculotomy, 
achieved a good IOP lowering effect. The number of topical antiglaucoma 
medications was significantly reduced as well. The safety and efficacy of the 
procedure was as high as the originally intended canaloplasty.  
4. Zusammenfassung 
Die Kanaloplastik ist ein neues Verfahren in der Glaukomchirurgie mit einem 
hohen Sicherheitsprofil. Ein wesentlicher Vorteil dieses Verfahrens liegt in der 
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schnellen postoperativen Genesung, die eine verbesserte Lebensqualität für die 
Patienten bedeutet.  
In dieser Dissertationsarbeit werden die Ergebnisse von zwei Studien zur 
langfristigen Wirksamkeit der Kanaloplastik sowie zum Umgang mit einer 
befürchteten intraoperativen Komplikation. In der ersten Studie konnte gezeigt 
werden, dass der drucksenkende Effekt der Kanaloplastik im Verlauf allmählich 
nachlässt, so dass nach 5 Jahren bei mehr als die Hälfte der Patienten eine 
zweite Operation erforderlich wurde.  Die Kanaloplastik demonstrierte ein sehr 
hohes Sicherheitsprofil. Visusbedrohende Komplikationen, wie aus der 
fistulierenden Chirurgie bekannt, sind nicht zu erwarten. Da keine chirurgische 
Maßnahme eine permanente Druckregulation bisher gewährleisten kann, bietet 
die Kanaloplastik eine stufenweise Glaukomtherapie. Die erste Stufe bildet die 
erfolgreich durchgeführte Kanaloplastik. Sobald der Effekt der Kanaloplastik 
nachlässt, kann der Faden aus dem Schlemm’schen Kanal entfernt werden 
(mikroinvasive Faden-Trabekulotomie) gefolgt von einer klassischen 
Trabekulektomie falls zum späteren Zeitpunkt erforderlich. 
Die Kanaloplastik ist jedoch chirurgisch anspruchsvoll. Chirurgische Erfahrung, 
individuelle anatomische Variationen und Steifheit der verwendete Katheter, 
sind wichtige Faktoren, die den Erfolg des Eingriffs bestimmen. In bis zu 15% 
der Augen kann der Schlemm‘sche-Kanal nicht kathetarisiert werden, oder der 
Spannungsfaden kann nicht eingesetzt werden. In diesen Fällen kann der 
Eingriff in in eine 180- oder 360-Grad Trabekulotomie umgewandelt werden. 
Die Ergebnisse der zweiten Studie zeigen, dass diese Strategie eine 
signifikante Drucksenkung mit einer deutlichen Reduktion der Augentropfen 
erreichen kann.  
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